VYNE Therapeutics Inc.
VYNE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 144.9% | -65.8% | 140.5% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $5 | $5 | $6 | $10 |
| G&A Expenses | $0 | $3 | $3 | $3 |
| SG&A Expenses | $3 | $3 | $3 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $8 | $8 | $9 | $13 |
| Operating Income | -$8 | -$8 | -$9 | -$13 |
| % Margin | -4,610.7% | -10,930.4% | -4,553% | -15,202.4% |
| Other Income/Exp. Net | $0 | $2 | $1 | $1 |
| Pre-Tax Income | -$7 | -$6 | -$9 | -$12 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$7 | -$6 | -$9 | -$12 |
| % Margin | -4,307.7% | -8,340.6% | -4,262.9% | -14,311.9% |
| EPS | -0.17 | -0.13 | -0.2 | -0.28 |
| % Growth | -30.8% | 35% | 28.6% | – |
| EPS Diluted | -0.17 | -0.13 | -0.2 | -0.28 |
| Weighted Avg Shares Out | 43 | 43 | 43 | 43 |
| Weighted Avg Shares Out Dil | 43 | 43 | 43 | 43 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$7 | -$8 | -$9 | -$13 |
| % Margin | -4,390.5% | -10,921.7% | -4,550% | -15,202.4% |